roflumilast roflumilast roflumilast, sold under the trade name daxas among others, is a drug that acts as a selective, long-acting inhibitor of the enzyme phosphodiesterase-4 (pde-4). it has anti-inflammatory effects and is used as an orally administered drug for the treatment of inflammatory conditions of the lungs such as chronic obstructive pulmonary disease (copd). roflumilastclinical datatrade namesdaxas, daliresp, zoryve, othersahfs/drugs.commonographmedlineplusa611034license data eu ema: by inn us dailymed: roflumilast us fda: roflumilast pregnancycategory au: b3 routes ofadministrationby mouth, topicalatc coder03dx07 (who) legal statuslegal status au: s4 (prescription only) ca: ℞-only uk: pom (prescription only) us: ℞-only eu: rx-only pharmacokinetic databioavailability79%protein binding99%metabolismhepatic via cyp1a2 & cyp3a4elimination half-life17 hours (30 hours )excretionurine (70%)identifiers iupac name 3-(cyclopropylmethoxy)-n-(3,5-dichloropyridin-4-yl)-4-(difluoromethoxy)benzamide cas number162401-32-3 npubchem cid449193iuphar/bps6962drugbankdb01656 ychemspider395793 nunii0p6c6zop5ukeggd05744chebichebi:47657 nchemblchembl193240 npdb ligandrof (pdbe, rcsb pdb)comptox dashboard (epa)dtxsid8044123 echa infocard100.210.960 chemical and physical dataformulac17h14cl2f2n2o3molar mass403.21 g·mol−13d model (jsmol)interactive image smiles c1cc1coc2=c(c=cc(=c2)c(=o)nc3=c(c=nc=c3cl)cl)oc(f)f inchi inchi=1s/c17h14cl2f2n2o3/c18-11-6-22-7-12(19)15(11)23-16(24)10-3-4-13(26-17(20)21)14(5-10)25-8-9-1-2-9/h3-7,9,17h,1-2,8h2,(h,22,23,24) nkey:mndbxuuturyvhr-uhfffaoysa-n n ny (what is this?) (verify) in june 2010, it was approved in the european union for severe copd associated with chronic bronchitis. in february 2011, it gained fda approval in the united states for reducing copd exacerbations. it is available as a generic medication. medical uses roflumilast is indicated for the treatment of severe chronic obstructive pulmonary disease (copd) and for the treatment of plaque psoriasis. it is used in the prevention of exacerbations (lung attacks) in severe chronic obstructive pulmonary disease (copd). adverse effects common (1–10% incidence) adverse effects include: diarrhea weight loss nausea headache insomnia decreased appetite abdominal pain rhinitis sinusitis urinary tract infection depression